NASDAQ: GOVXGeovax Labs Inc Stock
$1.54-0.01 (-0.65%)
Updated Apr 23, 2024
GOVX Price
$1.54
Fair Value Price
$3.55
Market Cap
$3.35M
52 Week Low
$1.45
52 Week High
$11.54
P/E
-0.11x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$25M
Beta
0.03
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GOVX Overview
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GOVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GOVX ($1.54) is undervalued by 56.63% relative to our estimate of its Fair Value price of $3.55 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GOVX ($1.54) is significantly undervalued by 56.63% relative to our estimate of its Fair Value price of $3.55 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GOVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOVX due diligence checks available for Premium users.
Be the first to know about important GOVX news, forecast changes, insider trades & much more!
GOVX News
Valuation
GOVX fair value
Fair Value of GOVX stock based on Discounted Cash Flow (DCF)
Price
$1.54
Fair Value
$3.55
Undervalued by
56.63%
GOVX ($1.54) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOVX ($1.54) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GOVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
16.46x
Market
41.92x
GOVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.93x
GOVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GOVX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.6M
Profit Margin
0%
GOVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.3M
Liabilities
$3.5M
Debt to equity
0.61
GOVX's short-term assets ($7.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOVX's short-term assets ($7.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOVX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GOVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.3M
Investing
-$18.9k
Financing
$4.1M
GOVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GOVX vs Biotech Stocks
Geovax Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.